Phase III trial to Evaluate the Efficacy of Maintaining Hemoglobin Levels Above 120 g/L with Erythropoietin Versus Above 100 g/L without Erythropoietin in Anemic Patients Receiving Concurrent Radiation and Cisplatin for Cervical Cancer

A Phase II Study of Tailored Adjuvant Therapy in POLE-mutated and p53-wildtype/NSMP Early Stage Endometrial Cancer (RAINBO BLUE & TAPER)

A Phase III Randomized Trial Comparing TAH BSO versus TAH BSO Plus Adjuvant Pelvic Irradiation in Intermediate Risk, Carcinoma of the Endometrium

Randomized Phase III Trial Comparing Concurrent Chemoradiation and Adjuvant Chemotherapy with Pelvic Radiation Alone in High Risk and Advanced Stage Endometrial Carcinoma.

A Randomized Phase III Trial of Weekly Parenteral Methotrexate Versus "Pulsed" Dactinomycin for Primary Management of Low Risk Gestational Trophoblastic Neoplasia

Intergroup Phase III Comparison of a Combination of TAXOL-Platinum and a Combination of Cyclophosphamide-Platinum Chemotherapy in the Treatment of Advanced Epithelial Ovarian Cancer.

A Phase II Trial of Intraperitoneal Cisplatin and Intravenous and Intraperitoneal Paclitaxel in Women with Optimally-Debulked Stage III Epithelial Ovarian Cancer

A Phase III Study of Cisplatin Plus Topotecan Followed by Paciltaxel plus Carboplatin versus Paclitaxel plus Carboplatin as First Line Chemotherapy in Women with Newly Diagnosed Advanced Epithelial Ovarian Cancer

A Randomised, Placebo-controlled, Trial of Concurrent Cediranib [AZD2171] (with platinum-based chemotherapy) and Concurrent and Maintenance Cediranib in Women with Platinum-sensitive Relapsed Ovarian Cancer

A Randomized, Two-Arm, Multi-Center Gynecologic Cancer Intergroup Trial of Adding Bevacizumab To Standard Chemotherapy (Carboplatin And Paclitaxel) In Patients With Epithelial Ovarian Cancer.

A Phase II Study of Intraperitoneal (IP) Plus Intravenous (IV) Chemotherapy Versus IV Carboplatin Plus Paclitaxel in Patients With Epithelial Ovarian Cancer Optimally Debulked at Surgery Following Neoadjuvant Intravenous Chemotherapy.

A Randomized Phase II Double-Blind Placebo-Controlled Trial of Acetylsalicylic Acid (ASA) in Prevention of Ovarian Cancer in Women with BRCA 1/2 Mutations (STICs and STONEs)

Disease Site	Trial Code	Patients Accrued	Patients - Blocks	Patients - Slides	Patients - Blocks and/or Slides
GYNECOLOGIC	CX4	19	0	0	0
GYNECOLOGIC	EN10	Open Trial	44	5	49
GYNECOLOGIC	EN5	116	15	99	100
GYNECOLOGIC	EN7	65	2	0	2
GYNECOLOGIC	GT1	23	0	1	1
GYNECOLOGIC	OV10	160	16	2	18
GYNECOLOGIC	OV11	7	0	1	1
GYNECOLOGIC	OV16	819	318	362	367
GYNECOLOGIC	OV18	87	32	42	68
GYNECOLOGIC	OV19	118	2	12	14
GYNECOLOGIC	OV21	275	17	43	59
GYNECOLOGIC	OV25	117	0	71	71

(Core size is 0.6 mm)

Disease Site	Trial Code	Patients Accrued	TMA Blocks	Patients on TMA Blocks
GYNECOLOGIC	CX4	19	0	0
GYNECOLOGIC	EN10	Open Trial	0	0
GYNECOLOGIC	EN5	116	0	0
GYNECOLOGIC	EN7	65	1	52
GYNECOLOGIC	GT1	23	0	0
GYNECOLOGIC	OV10	160	0	0
GYNECOLOGIC	OV11	7	0	0
GYNECOLOGIC	OV16	819	9	301
GYNECOLOGIC	OV18	87	1	5
GYNECOLOGIC	OV19	118	1	13
GYNECOLOGIC	OV21	275	2	28
GYNECOLOGIC	OV25	117	0	0

Disease Site	Trial Code	Patients Accrued	Patients - Whole Blood	Patients - Cellular Component of Blood	Patients - DNA extracted from Blood	Patients - RNA extracted from Blood	Patients - Plasma	Patients - Serum	Patients - Urine	Patients - Buccal
GYNECOLOGIC	CX4	19	0	0	0	0	0	0	0	0
GYNECOLOGIC	EN10	Open Trial	0	0	0	0	0	0	0	0
GYNECOLOGIC	EN5	116	0	0	0	0	0	0	0	0
GYNECOLOGIC	EN7	65	0	0	0	0	0	0	0	0
GYNECOLOGIC	GT1	23	0	0	0	0	0	0	0	0
GYNECOLOGIC	OV10	160	0	0	0	0	0	0	0	0
GYNECOLOGIC	OV11	7	0	0	0	0	0	0	0	0
GYNECOLOGIC	OV16	819	0	0	0	0	0	0	0	0
GYNECOLOGIC	OV18	87	74	0	0	0	0	0	0	0
GYNECOLOGIC	OV19	118	0	0	0	0	0	0	0	0
GYNECOLOGIC	OV21	275	0	0	0	0	0	0	0	0
GYNECOLOGIC	OV25	117	80	0	0	0	111	95	0	0